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Summary
Background.  —  A  new  generation  of  balloon-expandable  valves  (e.g.  Edwards  SAPIEN  XT)  enables
the  use  of  a  decreased  sheath  size  using  the  NovaFlexTM delivery  system  for  transfemoral  tran-
scatheter  aortic  valve  implantation  (TAVI).  However,  there  are  few  data  analysing  the  efﬁcacy
and  safety  of  this  new  prosthesis.
Abbreviations: AKI, acute kidney disease; BAV, balloon aortic valvuloplasty; CT, computed tomography; TAVI, transcatheter aortic
alve implantation; TTE, transthoracic echocardiography; VARC, Valve Academic Research Consortium.
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Aims.  —  To  evaluate  periprocedural  and  30-day  clinical  outcomes  using  the  Edwards  SAPIEN  XT
compared  with  the  ﬁrst-generation  Edwards  SAPIEN  prosthesis.
Methods.  —  Between  May  2006  and  October  2011,  consecutive  high-risk  or  non-operable  patients
with  severe  aortic  stenosis  had  TAVI  using  an  Edwards  SAPIEN  or  SAPIEN  XT  prosthesis.  Valve
Academic  Research  Consortium  endpoints  were  used.
Results.  —  Of  250  patients  who  underwent  TAVI,  190  were  performed  transfemorally  (78  SAPIEN
and  112  SAPIEN  XT).  Transfemoral  access  was  possible  more  often  using  SAPIEN  XT  (112/123
[91.1%]  vs  78/127  [61.4%];  P  <  0.001).  Mean  logistic  EuroSCORE  was  signiﬁcantly  lower  in  the
SAPIEN  XT  group  (18.1  ±  11.0%  vs  27.3  ±  11.1%;  P  <  0.0001),  and  the  iliofemoral  artery  minimal
lumen  diameter  was  smaller  (6.7  ±  1.2  vs  8.5  ±  1.3  mm;  P  <  0.0001).  Device  success  was  similar
in  both  groups  (95.5%  for  SAPIEN  XT  and  93.6%  for  SAPIEN),  as  was  the  30-day  combined  safety
endpoint  (15.2%  and  17.9%,  respectively).  At  30  days,  prosthesis  performance  was  similar  in
both  groups.
Conclusions.  —  Short-term  safety  and  performance  analysis  of  the  latest  generation  of  balloon-
expandable  valve,  the  SAPIEN  XT,  seem  similar  to  the  previous  generation.  However,
transfemoral implantation  is  more  often  possible,  related  to  sheath  size  reduction.
© 2012  Elsevier  Masson  SAS.  
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Résumé
Contexte.  —  Des  améliorations  techniques  ont  permis  récemment  le  développement  d’une
nouvelle génération  de  bioprothèses  aortiques,  la  valve  Edwards  SAPIEN  XT,  permettant  prin-
cipalement  de  diminuer  la  taille  des  désilets  nécessaires  lors  de  son  implantation  par  voie
transfémorale.  Cependant,  il  y  a  peu  de  données  analysant  l’efﬁcacité  et  la  sécurité  de  cette
nouvelle  prothèse.
Buts. — Évaluer  la  sécurité  et  l’efﬁcacité  de  la  valve  Edwards  SAPIEN  XT  en  comparaison  avec
le  modèle  de  première  génération,  la  valve  Edwards  SAPIEN.
Méthodes.  — Entre mai  2006  et  octobre  2011,  190  patients  consécutifs  présentant  un  rétrécisse-
ment aortique  considérés  à  haut  risque  ou  non  opérables,  ont  été  traités  par  l’implantation
d’une bioprothèse  aortique  par  voie  transfémorale  en  utilisant  soit  la  valve  Edwards  SAPIEN
(n  =  78),  soit  le  modèle  SAPIEN  XT  (n  =  112).  Les  critères  de  jugement  ont  été  évalués  selon  les
déﬁnitions  de  la  Valve  Academic  Research  Consortium  (VARC).
Résultats.  —  L’Euroscore  logistique  était  signiﬁcativement  plus  bas  dans  le  groupe  SAPIEN  XT  que
dans  le  groupe  Edward  SAPIEN  (18,1  ±  11,0  %  vs  27,3  ±  11,1  %  ;  p  <  0,0001).  Le  diamètre  minimal
de  la  lumière  artérielle  était  plus  petit  dans  le  groupe  SAPIEN  XT  (6,75  ±  1,17  vs  8,53  ±  1,32  mm  ;
p  <  0,0001).  Un  abord  transfémoral  a  été  plus  souvent  possible  avec  la  valve  SAPIEN  XT  (91,1  %
vs  61,4  %  ;  p  <  0,001).  Le  succès  de  la  procédure  a  été  similairement  élevé  dans  les  deux  groupes
(95,5  %  vs  93,6  %  ;  p  =  0,65).  Le  critère  combiné  de  sécurité  à  30  jours  selon  les  déﬁnitions  VARC
s’est  avéré  comparable  dans  les  deux  groupes  (15,2  %  vs  17,9  %  ;  p  =  0,61).  À  30  jours,  la  per-
formance  des  deux  modèles  de  valve  était  identique  (gradient  moyen  aortique  :  9,6  ±  2,6  vs
9,8  ±  3,7  mm  Hg  ;  p  =  0,76  ;  régurgitation  aortique  ≥  grade  III  :  4,3  %  vs  3,2  %  ;  p  =  0,92).
Conclusions. —  La  performance  et  les  taux  de  complications  à  30  jours  de  la  nouvelle  valve
SAPIEN XT  implantée  par  voie  transfémorale  semblent  similaires  à  ceux  de  la  valve  SAPIEN  de
première  génération.  Cependant,  grâce  à  la  réduction  de  taille  du  matériel,  un  abord  par  voie
transfémorale  est  maintenant  possible  dans  90  %  des  cas.
©  2012  Elsevier  Masson  SAS.  
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Since  the  ﬁrst-in-man  transcatheter  aortic  valve  implanta-
tion (TAVI)  in  2002,  many  registries  have  shown  that  TAVI
can be  accomplished  in  non-operable  and  high-risk  patients
with outcomes  that  compare  favourably  with  surgical  aor-
tic valve  replacement  [1—8].  This  has  been  observed  with
the two  devices  currently  in  use:  the  balloon-expandable
Edwards SAPIEN  (Edwards  Lifesciences  LLC,  Irvine,  CA,  USA)
and the  self-expandable  Medtronic  CoreValve  (Medtronic  CV,
Irvine,  CA,  USA)  prostheses.
g
E
s
eThe  ﬁrst-generation  balloon-expandable  valve  (Edwards
APIEN) required  22  F  and  24  F  sheaths  for  the  23-  and
6-mm valve  sizes,  respectively,  for  transfemoral  insertion
sing the  RetroFlexTM delivery  system.  The  large  sheath
ize was  the  most  important  limitation  of  this  technique.
ince October  2009,  subsequent  technical  and  procedu-
al improvements  have  allowed  the  development  of  a  new
eneration of  balloon-expandable  valves  such  as  the
dwards SAPIEN  XT,  which  decreased  the  required  sheath
ize to  18  F  and  19  F,  respectively,  using  the  NovaFlexTM deliv-
ry system.
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Using  the  SAPIEN  valve,  the  pivotal  randomized  Place-
ent of  Aortic  Transcatheter  Valve  Trial  US  (PARTNER-US)
rial demonstrated  the  superiority  of  TAVI  over  standard
are, with  a  marked  reduction  in  the  mortality  rate  at  1  year
n non-surgical  candidates  and  a  similar  rate  of  survival  at
 year  with  TAVI  and  surgical  aortic  valve  replacement  in
igh-surgical-risk patients  [9,10].  Only  limited  data,  how-
ver, are  available  for  the  Edwards  SAPIEN  XT  valve  [11,12].
hus, we  sought  to  compare  30-day  clinical  outcomes  in  our
rospective registry  using  Edwards  SAPIEN  XT  and  SAPIEN
rostheses.
ethods
atient selection and evaluation
etween  May  2006  and  October  2011,  consecutive  high-
isk patients  underwent  TAVI  using  balloon-expandable
dwards prostheses,  and  were  included  in  a  prospective,
ingle-centre registry.  All  patients  had  severe,  degenera-
ive symptomatic  aortic  stenosis.  The  indication  for  TAVI
as based  on  the  decision  of  the  medicosurgical  team.  The
atients were  considered  candidates  for  TAVI  when  their
ogistic EuroSCORE  was  greater  or  equal  to  20%,  in  case  of
railty, or  in  case  of  comorbidities  contraindicating  surgi-
al aortic  valve  replacement.  All  patients  provided  signed
nformed consent  for  subsequent  data  collection  and  analy-
is for  research  purposes.
The screening  process  included  transthoracic  echocardio-
raphy (TTE),  selective  coronary  angiography,  aortography,
liofemoral angiography  and  computed  tomography  (CT)  of
he aorta  and  iliofemoral  access.  Transoesophageal  echocar-
iography was  not  used  in  our  institution  to  assess  aortic
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igure 1. Edwards SAPIEN (A) and SAPIEN XT (B) prostheses and their
Edwards Lifesciences, Inc., Irvine, CA, USA). Sizes of the valves and diaH.  Eltchaninoff  et  al.
nnulus  diameter.  All  patients  with  unstable  haemodynam-
cs were  stabilized  with  balloon  aortic  valvuloplasty  (BAV)
efore TAVI.
An annulus  diameter  of  18—21  mm  was  considered
ppropriate  for  the  23-mm  prosthesis  and  21—24  mm
or the  26-mm  prosthesis.  In  cases  of  borderline  sizes
20.5—21.5 mm),  aortography  was  performed  during  balloon
redilatation with  a  23-mm  balloon,  and  the  optimal  valve
ize was  selected  based  on  the  presence  or  absence  of  aortic
egurgitation at  full  balloon  inﬂation.
CT  was  crucial  to  assess  the  feasibility  of  a  transfemoral
pproach. A  minimum  diameter  of  7  and  8  mm  was  required
or the  23-  and  26-mm  SAPIEN  valves,  respectively,  and  6  and
.5 mm  for  the  23-  and  26-mm  SAPIEN  XT  valves,  respec-
ively. Before  percutaneous  implantation,  tortuosities,  as
ell as  the  absence  of  calciﬁed  plaque  at  the  area  of  femoral
uncture site,  were  assessed  to  conﬁrm  the  suitability  for  a
emoral approach.
evices
he  procedures  were  performed  using  the  SAPIEN  valve
Fig. 1A)  up  to  October  2009  and  the  SAPIEN  XT  valve
Fig. 1B)  thereafter.  The  SAPIEN  valve  (Fig.  1A)  is  made
f three  bovine  pericardial  leaﬂets,  matched  for  elasticity
nd thickness,  sewn  onto  a  stainless  steel  stent  frame  par-
ially covered  with  a  synthetic  polyethylene  terephthalate
abric sealing  cuff.  The  prosthesis  is  crimped  directly  onto
he balloon  of  the  RetroFlexTM delivery  system  (Fig.  1C),
he outer  diameters  of  which  are  8.4  and  9.2  mm  for  the
3- and  26-mm  SAPIEN  valves,  respectively.  The  SAPIEN
T valve  (Fig.  1B)  is  made  of  a  cobalt  chromium  frame
ith thinner  struts  and  a  more  open  cell  structure  to  allow
ighter crimping.  The  valve  is  crimped  over  the  shaft  of  the
 respective delivery systems, RetroFlexTM (C) and NovaFlexTM (D)
meters of the sheaths are shown.
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sEdwards  SAPIEN  XT  prosthesis  and  TAVI  
NovaFlexTM delivery  system  (Fig.  1D)  and  mounted  on  the
balloon after  introduction  into  the  abdominal  aorta.  The
NovaFlexTM delivery  system  allows  a  reduction  in  sheath  size
to 18  F  (outer  diameter  7.2  mm)  and  19  F  (outer  diameter
7.5 mm)  for  the  23-  and  26-mm  valve  sizes,  respectively.
Patient preparation and procedure
Cardiac  catheterization  and  premedication
All  procedures  were  performed  in  a  conventional  cardiac
catheterization laboratory  with  sterile  precautions,  using
local anaesthesia  and  conscious  sedation  in  all  cases.  Surgi-
cal arterial  cut-down  was  performed  by  our  cardiac  surgeon
for SAPIEN  implantation,  whereas  most  cases  were  per-
formed using  a  percutaneous  approach  with  pre-closing  for
SAPIEN XT  implantation.  For  the  latter  approach,  the  cardiac
surgeon was  not  always  present.  All  of  the  equipment  was
present and  ready  to  use  in  the  catheterization  laboratory,
and both  the  anaesthesiologist  and  the  echocardiographer
were immediately  available  in  the  event  of  any  complica-
tion.
Patients were  preloaded  with  aspirin  (160  mg)  and
clopidogrel (300  mg),  and  continued  clopidogrel  (75  mg)
for 1  month  and  aspirin  (75—160  mg)  indeﬁnitely.  Heparin
(5000 IU)  was  administered  immediately  after  surgical  cut-
down or  placement  of  the  vascular  closure  device.
Local  anaesthesia  and  sedation
Lidocaine  2%  (20—30  mL)  was  used  for  local  anaesthesia,
injected into  the  skin  and  subcutis,  and  around  the  femoral
artery for  percutaneous  and  surgical  approaches.  Additional
doses of  lidocaine  could  be  administered  at  any  time  during
the procedure  at  the  discretion  of  the  operator.  Conscious
sedation consisted  of  intravenous  administration  of  mida-
zolam (1  mg)  and  nalbuphin  (5  mg)  at  the  start  of  the
procedure. Additional  half  or  full  doses  of  each  could  be
administered at  the  discretion  of  the  operator  during  the
course of  the  procedure.
Procedure
The  techniques  of  SAPIEN  and  SAPIEN  XT  valve  implanta-
tion have  been  described  in  detail  elsewhere  [9—11].  Brieﬂy,
in our  centre,  supravalvular  aortography  was  performed  to
select the  optimal  view,  aligning  all  cusps  in  a  single  plane.
The selected  femoral  artery  was  cut-down  or  ‘pre-closed’
with a  10  F  Prostar  XLTM (Abbott  Inc.,  Chicago,  IL,  USA).  After
crossing the  aortic  valve,  a  260-cm  long  0.035  inch  Amplatz
Extra-Stiff J-tip  guidewire  (COOK,  Bjaeverskov,  Denmark)
was placed  in  the  left  ventricle.  BAV  was  performed  with
rapid ventricular  pacing  (180—220  beats/min)  using  a  20-
or 23-mm  balloon  in  accordance  with  the  valve  size.  Valve
positioning was  based  on  ﬂuoroscopy,  using  annular  calciﬁ-
cation as  a  landmark,  and  serial  (5—10  mL)  supra-annular
aortography to  validate  the  position  of  the  valve  during
rapid ventricular  pacing.  The  prosthesis  was  also  delivered
using rapid  ventricular  pacing.  Removal  of  the  sheath  was
cautiously achieved  with  serial  contralateral  angiograms  to
detect iliofemoral  complications.  The  femoral  arteriotomy
was then  closed  surgically  or  using  the  Prostar  device.  In  the
absence of  a  new  left  bundle  branch  block  or  atrioventric-
ular block,  the  pacing  lead  was  removed  at  the  end  of  the
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rocedure.  Patients  were  monitored  in  the  intensive  care
nit for  24  hours  after  valve  implantation.
ata collection
ata  on  clinical  and  TTE  variables  were  obtained  at  base-
ine, discharge  and  1  month,  and  were  entered  into  our
nstitutional database.  In  patients  from  remote  institutions,
utcomes at  30  days  were  obtained  by  telephone  interviews
f the  referring  physician  and  exchange  of  TTE  reports.  No
atients were  lost  to  follow-up.
ndpoint deﬁnitions
he  safety  endpoint  was  a  combination  of  all-cause  mortal-
ty, major  stroke,  life-threatening  bleeding,  stage  3  acute
idney injury  (AKI),  periprocedural  myocardial  infarction,
ajor vascular  complication,  and  repeat  procedure  for
alve-related dysfunction  at  30  days.  All  complications  were
eported  according  to  the  Valve  Academic  Research  Consor-
ium (VARC)  classiﬁcation  [13].
Other  endpoints  included:  device  success  according  to
he VARC  deﬁnition  (i.e.  successful  vascular  access,  deliv-
ry and  deployment  of  the  device,  successful  retrieval  of
he delivery  system  with  correct  position  of  the  device,  post-
AVI aortic  valve  area  greater  than  1.2  cm2 and  mean  aortic
alve gradient  less  than  20  mmHg  or  peak  velocity  less  than
 m/s  without  moderate  or  severe  prosthetic  valve  regurgi-
ation), New  York  Heart  Association  heart  failure  functional
lass, transvalvular  mean  pressure  gradient,  effective  aortic
alve  area,  presence  and  severity  of  aortic  valvular  regurgi-
ation, and/or  mitral  valve  regurgitation  on  TTE.
tatistical analysis
ontinuous  variables  are  presented  as  mean  ±  standard
eviation (SD)  or  median  (interquartile  range),  according  to
he distribution.  Categorical  variables  are  presented  as  fre-
uencies and  percentages.  We  used  student’s  t  test  or  the
anfred-Whitney test  to  compare  differences  between  con-
inuous variables,  and  the  Chi-square  or  Fisher’s  exact  test
o compare  differences  between  categorical  variables,  as
ppropriate. Differences  were  considered  statistically  sig-
iﬁcant at  P  values  less  than  0.05.  All  statistical  analysis
as performed  using  SPSS  Statistics  software  version  17.0
SPSS Inc.,  Chicago,  IL,  USA).
esults
aseline characteristics
uring  the  study  period  (May  2006  to  October  2011),  250
atients underwent  TAVI  at  our  centre,  all  using  balloon-
xpandable Edwards  prostheses.  A  transapical  access  was
sed in  60  patients  (24%),  while  190  (76%)  procedures  were
erformed using  a  transfemoral  access.  Thus,  the  current
tudy cohort  comprised  190  patients  who  underwent  trans-
emoral implantation  of  an  Edwards  prosthesis:  78  (41.1%)
ith the  SAPIEN  prosthesis  between  May  2006  and  Septem-
er 2009,  and  112  (58.9%)  with  the  SAPIEN  XT  prosthesis
etween October  2009  and  October  2011.  Signiﬁcantly  more
136  
Figure 2. Numbers of patients who underwent TAVI using a
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rocedures  using  the  SAPIEN  XT  versus  the  SAPIEN  prosthe-
is were  performed  using  a  transfemoral  approach  (112/123
91.1%] vs  78/127  [61.4%];  P  <  0.001;  Fig.  2).
Most patients  underwent  TAVI  for  severe,  degenerative
ymptomatic aortic  stenosis,  but  two  patients  in  the  SAPIEN
T group  had  a  degenerated  stenotic  aortic  bioprosthe-
is. Baseline  clinical  characteristics  are  shown  in  Table  1.
he mean  Logistic  EuroSCORE  was  signiﬁcantly  lower  in  the
APIEN XT  group  (18.1  ±  11.0%  vs  27.3  ±  11.1%;  P  <  0.0001).
w
l
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Table  1 Baseline  characteristics.
All  patients  (n  =  1
Age  (years)  83.3  ±  6.4  
Men 78  (41.3)  
Hypertension 134  (70.9)  
Diabetes 50  (26.5)  
Previous myocardial  infarction  42  (22.2)  
Previous  PCI  47  (24.9)  
Previous CABG 28  (14.8)  
Atrial ﬁbrillation 79  (41.8)
Pacemaker 17  (9.0)  
Previous BAV  77  (40.7)  
Peripheral  artery  disease  21  (11.1)  
Porcelain aorta  8  (4.2)  
Previous stroke  10  (5.3)  
Creatinine (mol/L)  113.3  ±  51.8  
Chronic obstructive  pulmonary  disease  57  (30.2)  
Chest irradiation  20  (10.6)  
Neoplasia 43  (22.8)  
New York  Heart  Association  ≥  III  145  (77.6)  
Logistic EuroSCORE,  %  21.9  ±  11.9  
Minimal  luminal  diameterof  iliofemoral
vessels on  therapeutic  side  (mm)
7.3  ±  1.5  
Data are mean ± SD or count (%). BAV: balloon aortic valvuloplasty; C
intervention.H.  Eltchaninoff  et  al.
istory  of  myocardial  infarction,  coronary  artery  bypass
raft and  BAV  were  also  signiﬁcantly  less  frequent  in  the
APIEN XT  group.  Patients  treated  with  SAPIEN  XT  had  a  sig-
iﬁcantly smaller  minimal  luminal  diameter  of  the  access
liofemoral arteries  than  those  treated  with  the  SAPIEN
rosthesis (Table  1).  All  other  variables  were  comparable
etween the  two  groups.
Baseline  TTE  data  (Table  2)  conﬁrmed  the  severity  of
ortic stenosis  in  both  groups.  Mean  aortic  gradient  was  sig-
iﬁcantly higher  in  the  SAPIEN  XT  group,  probably  because
ore patients  in  the  SAPIEN  group  were  previously  treated
y BAV.  Left  ventricular  ejection  fraction  was  also  signiﬁcan-
ly higher  in  the  SAPIEN  XT  group.  However,  the  proportion
f patients  with  left  ventricular  ejection  fraction  less  than
0% was  not  signiﬁcantly  different  in  the  two  groups.
eriprocedural outcomes
edation  and  local  anaesthesia,  used  in  all  cases,  was  well
olerated in  both  groups.  The  percutaneous  approach  was
erformed in  most  patients,  apart  from  two  in  the  SAPIEN
T group.
The prosthesis  was  placed  in  the  appropriate  position
n all  cases  with  successful  vascular  access.  A  single  valve
as implanted  in  189  out  of  190  cases  (99.5%)  (Table  3);
nd there  was  no  valve  embolization.  One  patient  of  the
APIEN XT  group  had  an  annulus  rupture  with  tamponade
equiring a  valve-in-valve  procedure.  Transient  haemostasis
as obtained,  but  the  patient  died  in  the  catheterization
aboratory.
Conversion to  emergent  cardiac  surgery  was  required  in
hree patients  (1.6%),  all  in  the  SAPIEN  group  (one  aortic
90)  SAPIEN  (n  =  78)  SAPIEN  XT  (n  =  112)  P
83.9  ±  5.8  82.7  ±  6.9  0.87
35  (44.9)  43  (38.7)  0.40
52  (66.7)  82  (73.9)  0.28
18  (23.1)  32  (28.8)  0.38
29  (37.2)  13  (11.7)  <  0.0001
22  (28.2)  25  (22.5)  0.37
18  (23.1)  10  (9.0)  0.007
29 (37.2)  50  (45.0)  0.28
10  (12.8)  7  (6.3)  0.12
49  (62.8)  28  (25.2)  <  0.0001
8  (10.3)  13  (11.7)  0.75
3  (3.8)  5  (4.5)  1.0
4  (5.1)  6  (5.4)  1.0
117.6  ±  42.7  108.6  ±  60.0  0.31
29  (37.2)  28  (25.2)  0.08
12  (15.4)  8  (7.2)  0.07
22  (28.2)  21  (18.9)  0.13
63  (80.8)  82  (75.2)  0.56
27.3  ±  11.1  18.1  ±  11.0  <  0.0001
8.5  ±  1.3  6.7  ±  1.2  <  0.0001
ABG: coronary artery bypass graft; PCI: percutaneous coronary
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Table  2  Baseline  echocardiographic  characteristics.
All  patients  (n  =  190)  SAPIEN  (n  =  78)  SAPIEN  XT  (n  =  112)  P
Aortic  annulus  diameter  (mm) 21.0  ±  3.0  20.6  ±  3.6  21.4  ±  1.9  0.48
Mean  aortic  gradient  (mmHg)  44.6  ±  17.1  41.4  ±  15.1  48.1  ±  18.1  0.004
Aortic  valve  area  (cm2)  0.67  ±  0.56  0.67  ±  0.16  0.66  ±  0.15  0.32
Pulmonary  artery  systolic  pressure  (mmHg)  42.7  ±  13.2  43.8  ±  12.4  41.7  ±  13.9  0.96
Left  ventricular  ejection  fraction  (%) 55.9  ±  15.6  52.7  ±  17.1  59.3  ±  13.3  0.04
Left  ventricular  ejection  fraction  <  30% 24 (12.6) 12  (15.4) 12  (10.7) 0.34
Data are mean ± SD or count (%).
Table  3 Procedural  outcomes.
All  patients  (n  =  190) SAPIEN  (n  =  78)  SAPIEN  XT  (n  =  112)  P
Surgical  cut-down  80  (42.1)  78  (100)  2  (1.8)  <  0.001
Conversion  to  general  anaesthesia 6  (3.2)  5  (6.5)  1  (0.9)  0.04
Vasopressors 11  (5.8) 6 (7.8)  5  (4.5)  0.34
Valve diameter 0.29
23 mm 96 (50.5) 36 (46.2)  60  (53.6)
26  mm 94 (49.5) 42 (53.8) 52 (46.4)
Device  success 180  (94.7) 73 (93.6)  107  (95.5)  0.65
Successful vascular  access 187  (98.4) 76 (97.4) 111 (99.1)  1.0
Successful implantation 187  (98.4)a 76  (100)a 111  (99.1)a 1.0
Correct position 187  (98.4)a 76  (100)a 111  (99.1)a 1.0
Aortic valve  area  >  1.2  cm2 187  (98.4)a 76  (100)a 111  (99.1)a 1.0
MAG <  20  mmHg 187  (98.4)a 76  (100)a 111  (99.1)a 1.0
Aortic regurgitation  ≥  grade  3 6 (3.2) 3 (3.8) 3 (2.7) 0.69
Only one  valve  implanted  186  (99.5)a 76  (100)a 110  (99.1)a 1.0
Post dilatation  12  (6.3)  7  (9.0)  5  (4.5)  0.33
Procedural duration  (min)  136.6  ±  47.0  151.7  ±  52.7  105.9  ±  42.3  <  0.001
X-ray  time  (min)  24.4  ±  18.3  25.9  ±  23.2  22.5  ±  9.0  0.10
Contrast volume  (mL)  185.2  ±  96.4  139.4  ±  53.7  242.5  ±  107.1  <  0.001
Emergency  cardiac  surgery  3  (1.6)  3  (3.8)  0  0.25
Data are mean ± standard deviation or count (%). MAG: mean aortic gradient.
a Events were only evaluated in patients with successful vascular access.
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(dissection,  one  aortic  annulus  rupture  with  tamponade  and
one major  aortic  regurgitation)  (Table  3).  Conversion  to
general anaesthesia  in  the  cardiac  catheterization  labo-
ratory before  transfer  to  the  operating  room  occurred  in
one patient  (annulus  rupture)  (Table  3).  Two  patients  (aor-
tic dissection  and  annulus  rupture  [mentioned  above])  did
not survive  surgery.  In  contrast,  in  the  SAPIEN  XT  group,
conversion to  general  anaesthesia  in  the  catheterization  lab-
oratory or  conversion  to  cardiac  surgery  was  never  required
(Table 3).  Urgent  vascular  surgery  was  required  in  seven
cases (3.7%),  with  no  signiﬁcant  difference  between  the  two
groups (5.1%  vs  2.7%;  P  =  0.45).
Haemodynamics  remained  remarkably  stable  at  each
step of  the  procedures.  Vasopressors  were  required  in
11 patients  (5.8%),  including  those  requiring  general
anaesthesia described  above  and  patients  who  had  pro-
longed hypotension  after  valve  delivery,  without  signiﬁcant
difference between  the  two  groups  (Table  3).  Procedural
duration was  signiﬁcantly  shorter  in  the  SAPIEN  XT  group,
whereas contrast  volume  was  signiﬁcantly  greater  in  this
r
v
f
lroup  (Table  3),  due  to  additional  use  of  contrast  associated
ith the  ‘pre-close’  technique.
The  overall  procedural  device  success  rate  was  94.7%,
nd was  similar  with  the  two  valves  (Table  3).  Procedu-
al failure  was  related  to:  unsuccessful  vascular  access  in
hree cases  (two  SAPIEN  and  one  SAPIEN  XT);  a  second  valve
mplantation (SAPIEN  XT);  and  severe  aortic  regurgitation
≥ grade  3)  in  six  cases  (three  in  each  group).
hirty-day safety outcomes
hirty-day  safety  outcomes  are  shown  in  Table  4.  In
he overall  population,  the  combined  30-day  safety  end-
oint was  reached  in  16.3%,  including  death  (6.3%),  major
troke (2.1%),  life-threatening  bleeding  (8.9%),  stage  3  AKI
0.5%),  major  vascular  complication  (7.9%),  periprocedu-
al myocardial  infarction  (2.1%),  and  repeat  procedure  for
alve-related dysfunction  (1.6%),  with  no  signiﬁcant  dif-
erence between  groups  (Table  4).  We  observed  a similar,
ow rate  of  major  stroke  and  periprocedural  myocardial
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Table  4 Thirty-day  safety  analysis.
All  patients  (n  =  190)  SAPIEN  (n  =  78)  SAPIEN  XT  (n  =  112)  P
Combined  safety  endpointa 31  (16.3)  14  (17.9)  17  (15.2)  0.61
Death 12  (6.3)  6  (7.7)  6  (5.4)  0.56
Stroke 7  (3.7)  2  (2.6)  5  (4.5)  0.49
Major 4 (2.1) 1  (1.3) 3  (2.7)
Minor 2 (1.1) 1  (1.3) 1  (0.9)
Transient  ischaemic  attack 1 (0.5) 0 1  (0.9)
Bleeding  49  (25.8)  16  (20.5)  33  (29.5)  0.11
Life-threatening  17  (8.9)  6  (7.7)  11  (9.8)
Major 22  (11.6)  9  (11.5)  13  (11.6)
Minor 10  (5.3)  1  (1.3)  9  (8.0)
Transfusions  50  (26.3)  26  (33.3)  24  (21.4)  0.07
Acute kidney  injury  41  (21.5)  25  (32.1)  16  (14.3)  0.07
Stage 3  1  (0.5)  1  (1.3)  0
Stage  2  1  (0.5)  1  (1.3)  0
Stage  1  39  (20.5)  23  (29.5)  16  (14.3)
Vascular  complications  43  (22.7)  13  (16.7)  30  (27.0)  0.10
Major 15  (7.9)  6  (7.7)  9  (8.1)
Minor 28  (14.8)  7  (9.0)  21  (18.9)
Periprocedural  myocardial  infarction  4  (2.1)  2  (2.6)  2  (1.8)  1.0
Tamponade 3  (1.6)  1  (1.3)  2  (1.8)  1.0
Emergency vascular  surgery  7  (3.7)  4  (5.1)  3  (2.7)  0.45
Pacemaker 11  (5.9)  5  (6.5)  6  (5.5)  0.77
Procedure to  CCU  discharge  (days)  1.0  (1.0—2.3)  1.5  (1.0—2.0)  1.0  (1.0—3.0)  0.95
Procedure to  discharge  (days)  7.0  (5.0—9.0)  8.0  (7.0—9.0)  5.5  (4.0—8.0)  <  0.001
Data are median (interquartile range) or count (%). CCU: coronary care unit.
a Combination of all-cause mortality, major stroke, life-threatening bleeding, stage 3 AKI, periprocedural myocardial infarction, major
vascular complication, and repeat procedure for valve-related dysfunction.
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Hnfarction  in  both  groups.  Life-threatening  and  major  bleed-
ngs were  not  signiﬁcantly  different  between  the  groups
Table 4),  but  minor  bleeding  was  more  frequent  in  the
APIEN XT  group  (8.0%  vs  1.3%;  P  =  0.049).  However,  the  need
or blood  transfusion  showed  a  trend  for  a  lower  rate  in  the
APIEN XT  group  (21.4%  vs  33.3%;  P  =  0.07).
Major vascular  complication  occurred  in  six  patients
7.7%) in  the  SAPIEN  group,  related  to  vascular  rupture
equiring urgent  surgery  in  four  cases  and  to  aortic  dissec-
ion in  two  cases  (one  requiring  unsuccessful  urgent  cardiac
urgery and  one  managed  medically  without  death).  Major
ascular complication  occurred  in  nine  patients  (8.1%)  in
he SAPIEN  XT  group,  all  related  to  failure  of  the  vascu-
ar closure  devices,  requiring  endovascular  stent  graft  in
ix patients  and  prolonged  manual  compression  in  three
ases. There  was  a  trend  towards  a  higher  rate  of  minor
g
M
(
S
Table  5 Thirty-day  secondary  endpoints.
All  patients  (n
New  York  Heart  Association  ≥  III 9 (10.3)
Mean  aortic  gradient  (mmHg) 9.7  ±  3.3
Aortic  valve  area  (cm2)  1.69  ±  0.49  
Left  ventricular  ejection  fraction  (%)  60.9  ±  12.2  
Aortic  regurgitation  ≥  grade  3 6 (3.7)  
Pulmonary  arterial  systolic  pressure  (mmHg)  40.4  ±  13.8  ascular  complication  in  the  SAPIEN  XT  group  (18.9%  vs  9.0%;
 =  0.058;  Table  4).  A  permanent  pacemaker  was  required  in
.9% of  the  overall  population,  with  no  signiﬁcant  difference
etween the  groups.  Finally,  median  hospital  stay  was  sig-
iﬁcantly shorter  in  the  SAPIEN  XT  group  (5.5  vs  8.0  days;
 <  0.001;  Table  4).
rosthesis performance
ew  York  Heart  Association  heart  failure  functional  class
as dramatically  improved  at  30  days  (Table  5  vs  Table  1).
aemodynamic  variables,  aortic  valve  area  and  mean  aortic
radient were  also  markedly  improved  (Table  5  vs  Table  2).
oderate  to  important  aortic  regurgitation  was  infrequent
≥ grade  3  in  3.7%).  Overall,  results  were  similar  in  the
APIEN and  SAPIEN  XT  groups.
 =  190) SAPIEN  (n  =  78)  SAPIEN  XT  (n  =  112)  P
5  (8.5)  4 (14.3)  0.40
9.6 ±  2.6 9.8 ±  3.7  0.76
1.67  ±  0.51  1.71  ±  0.48  0.69
58.5  ±  11.7  62.6  ±  12.2  0.04
3  (4.3)  3 (3.2)  0.92
40  ±  12  40.7  ±  14.8  0.77
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Discussion
The  main  ﬁndings  of  this  study  are:  (1)  introduction  of  the
SAPIEN XT  valve  and  NovaFlexTM delivery  system  allowed  the
performance of  transfemoral  TAVI  in  the  majority  of  patients
with smaller  iliofemoral  arteries,  related  to  sheath  size
reduction; (2)  transfemoral  TAVI  with  both  the  SAPIEN  XT  and
SAPIEN prostheses  was  associated  with  a  high  device  success
rate and  similar  periprocedural  and  short-term  outcomes
in high-risk  elderly  patients;  and  (3)  the  new-generation
SAPIEN XT  valve  has  the  same  short-term  performance  as
the SAPIEN  prosthesis.
The  large  sheath  diameter  required  for  valve  implan-
tation with  the  SAPIEN  prosthesis  was  the  most  important
limitation of  this  technique,  requiring  surgical  cut-down
for transarterial  access  in  all  patients.  Indeed,  about
40% of  eligible  patients  could  not  be  treated  with  a
transfemoral approach  using  this  valve,  and  underwent
transapical implantation.  The  introduction  of  the  SAPIEN
XT prosthesis  has  dramatically  improved  the  possibility  of
transfemoral implantation.  In  our  series,  the  rate  of  trans-
femoral approach  increased  from  61.4%  with  the  SAPIEN  to
91.1% with  the  SAPIEN  XT  prosthesis.  The  requirement  for  a
smaller iliofemoral  diameter,  the  low  risk  of  major  adverse
events, and  the  favourable  performance  of  the  SAPIEN  XT
prosthesis dramatically  extended  the  clinical  application  for
transfemoral TAVI,  which  can  now  be  performed  without
surgical cut-down  for  transarterial  access  using  pre-closing
vascular devices.
To the  best  of  our  knowledge,  there  are  few  reports
evaluating the  SAPIEN  XT  prosthesis.  The  ﬁrst  study  was
published in  2009  by  Webb  et  al.,  and  reported  favourable
short-term outcomes  in  three  patients  [11].  Very  recently,  a
single-centre observational  study  comparing  the  SAPIEN  XT
(n =  54)  and  SAPIEN  (n  =  66)  prostheses  in  120  patients  who
underwent transfemoral  TAVI  has  been  reported  by  Mussardo
et al.  [12].  They  observed  that  the  SAPIEN  XT  valve  had  the
same short-term  performance  as  the  SAPIEN  prosthesis,  but
was  associated  with  a  three-fold  lower  risk  of  major  vascular
complications (11.1%  vs  33.3%;  relative  risk  0.40,  95%  conﬁ-
dence interval  0.28—0.57;  P  =  0.004).  Other  complications,
such as  stroke,  AKI,  myocardial  infarction  and  bleeding  were
similar,  although  there  was  a  trend  for  a  lower  transfusion
rate in  the  SAPIEN  XT  group  [12].  Interestingly,  the  results
of our  observational  study  are  close  to  those  reported  by
Mussardo et  al.  as  per  the  device  success  rate  and  30-day
performance, both  similarly  high  with  the  two  prostheses.
However, we  did  not  observe  a  signiﬁcant  reduction  in  major
vascular complications  with  the  SAPIEN  XT.  However,  using
similar VARC  deﬁnitions,  the  incidence  of  major  vascular
events with  SAPIEN  XT  was  close  to  that  reported  by  Mus-
sardo et  al.  (8.1%  vs  11.1%  [12]).  In  our  experience,  all  major
vascular events  were  actually  related  to  failure  of  vascular
closure devices,  without  any  aortic  dissection  or  iliofemoral
rupture. In  contrast,  we  reported  a  lower  rate  of  major  vas-
cular complications  using  the  SAPIEN  valve  as  compared  to
their study  (7.7%  vs  33.3%  [12]).  This  discrepancy  may  be
related, in  their  study,  to  the  initial  learning  curve,  less
stringent patient  selection  and/or  a  higher  incidence  of  pre-
existent peripheral  arterial  disease.  Indeed,  in  our  registry,
we did  not  include  patients  without  CT  screening  to  assess
the suitability  for  a  transfemoral  approach.139
The main  limitations  of  this  study  are  its  observational
esign and  lack  of  randomization.  A  randomized  compari-
on of  the  SAPIEN  XT  and  SAPIEN  prostheses  has  recently
een required  by  the  US  Food  and  Drug  Administration.
owever, when  the  SAPIEN  XT  was  introduced  in  France,
he SAPIEN  valve  became  commercially  unavailable.  Fur-
hermore, this  prospective  study  reﬂects  a  single-centre
xperience on  a  relatively  limited  number  of  patients.  We
xcluded TAVI  patients  treated  before  May  2006  with  another
pproach (compassionate  procedures  or  anterograde  cases);
ther delivery  systems  (Retroﬂex  1  and  2);  and  a  different
creening process  (no  CT  angiography)  in  order  to  optimally
ompare the  two  devices  in  patients  with  similar  clini-
al evaluations.  Finally,  patients  treated  with  the  SAPIEN
T prosthesis  had  a  lower  risk  proﬁle  than  those  treated
sing the  SAPIEN  prosthesis.  However,  indications  of  TAVI
ave been  restricted  to  inoperable  and  high-surgical  risk
atients, and  all  decisions  were  made  by  the  medicosurgical
eam.
onclusions
hort-term  safety  and  performance  analysis  of  the  latest
eneration SAPIENT  XT  balloon-expandable  valve  seems
ery similar  to  the  previous  generation.  However,  trans-
emoral implantation  is  possible  more  often,  related  to
heath size  reduction.  The  Edwards  SAPIEN  XT  prosthesis
ight facilitate  the  expansion  of  transfemoral  TAVI  in  the
uture.
isclosure of interest
.C.:  Consultant  for  Edwards  Lifesciences.
.E.: Proctor  for  Edwards  Lifesciences.
.-Y.L.: Proctor  for  Edwards  Lifesciences.
ll other  authors  declare  that  they  have  no  conﬂicts  of  inter-
st concerning  this  article.
eferences
[1] Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous tran-
scatheter  implantation of an aortic valve prosthesis for calciﬁc
aortic stenosis: ﬁrst human case description. Circulation
2002;106:3006—8.
[2]  Cribier A, Eltchaninoff H, Tron C, et al. Treatment of calciﬁc
aortic  stenosis with the percutaneous heart valve: mid-term
follow-up  from the initial feasibility studies: the French expe-
rience. J Am Coll Cardiol 2006;47:1214—23.
[3] Thomas M, Schymik G, Walther T, et al. Thirty-day results of
the SAPIEN aortic Bioprosthesis European Outcome (SOURCE)
Registry:  a European registry of transcatheter aortic valve
implantation  using the Edwards SAPIEN valve. Circulation
2010;122:62—9.
[4]  Rodés-Cabau J, Webb JG, Cheung A, et al. Transcatheter aortic
valve  implantation for the treatment of severe symptomatic
aortic  stenosis in patients at very high or prohibitive surgi-
cal  risk: acute and late outcomes of the multicenter Canadian
experience.  J Am Coll Cardiol 2010;55:1080—90.
[5] Lefèvre  T, Kappetein AP, Wolner E, et al. One year follow-up of
the multi-centre European PARTNER transcatheter heart valve
study. Eur Heart J 2011;32:148—57.
1[
[
[40  
[6] Eltchaninoff H, Prat A, Gilard M, et al. Transcatheter aor-
tic  valve implantation: early results of the FRANCE (FRench
Aortic  National CoreValve and Edwards) registry. Eur Heart J
2011;32:191—7.
[7] Tamburino C, Capodanno D, Ramondo A, et al. Incidence and
predictors of early and late mortality after transcatheter aortic
valve  implantation in 663 patients with severe aortic stenosis.
Circulation  2011;123:299—308.
[8] Zahn R, Gerckens U, Grube E, et al. Transcatheter aortic valve
implantation:  ﬁrst results from a multi-centre real-world reg-
istry. Eur Heart J 2011;32:198—204.
[9] Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve
implantation for aortic stenosis in patients who cannot undergo
surgery. N Engl J Med 2010;363:1597—607.
[H.  Eltchaninoff  et  al.
10] Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus
aortic-valve  replacement in high-risk patients. N Engl J Med
2011;364:2187—98.
11] Webb JG, Altwegg L, Masson JB, et al. A new transcatheter
aortic  valve and percutaneous valve delivery system. J Am Coll
Cardiol 2009;53:1855—8.
12] Mussardo M, Latib A, Chieffo A, et al. Periprocedural and short-
term outcomes of transfemoral transcatheter aortic valve
implantation  with the Sapien XT as compared with the Edwards
Sapien  valve. JACC Cardiovasc Interv 2011;4:743—50.13] Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint
deﬁnitions  for transcatheter aortic valve implantation clinical
trials: a consensus report from the Valve Academic Research
Consortium.  Eur Heart J 2011;32:205—17.
